Optimizing preclinical study design in oncology research

Chemico-Biological Interactions

Volumn 190, Issue 2-3, 2011, Pages 73-78

  Wittenburg, Luke A ^a   Gustafson, Daniel L ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Oncology; Pharmacodynamics; Pharmacokinetics; Preclinical study

Indexed keywords

DOXORUBICIN; IRINOTECAN; MURAMYL TRIPEPTIDE; NAVELBINE;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER SURVIVAL; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; EVENT FREE SURVIVAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; REVIEW; STUDY DESIGN; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; METABOLIC DETOXICATION, DRUG; PROTEINS;

EID: 79955473361     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.01.029     Document Type: Review

References (32)

1. S. Kummar, R. Kinders, L. Rubinstein, R.E. Parchment, A.J. Murgo, J. Collins, O. Pickeral, J. Low, S.M. Steinberg, M. Gutierrez, S. Yang, L. Helman, R. Wiltrout, J.E. Tomaszewski, and J.H. Doroshow Compressing drug development timelines in oncology using phase '0' trials Nature reviews 7 2 2007 131 139 (Pubitemid 46160988)
2. M. Rowland, and T.N. Tozer Why clinical pharmacokinetics? D. Balado, Clinical Pharmacokinetics: Concepts and Applications 1995 Williams & Wilkins Media, PA 1 7
3. J. Gabrielsson, A.R. Green, and P.H. Van der Graaf Optimising in vivo pharmacology studies - practical PKPD considerations Journal of Pharmacological and Toxicological Methods 61 2 2010 146 156
4. J. Gabrielsson, and A.R. Green Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology The Journal of Pharmacology and Experimental Therapeutics 331 3 2009 767 774
5. B.M. Agoram, S.W. Martin, and P.H. van der Graaf The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics Drug Discovery Today 12 23-24 2007 1018 1024 (Pubitemid 350180561)
6. J.L. Sottnik, D.L. Duval, E.J. Ehrhart, and D.H. Thamm An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis Clinical and Experimental Metastasis 27 3 2010 151 160
7. N Federman, N. Bernthal, F.C. Eilber, and W.D. Tap The multidisciplinary management of osteosarcoma Current Treatment Options in Oncology 10 1-2 2009 82 93
8. I. Gordon, M. Paoloni, C. Mazcko, and C. Khanna The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway PLoS Medicine 6 10 2009 e1000161
9. C. Khanna, K. Lindblad-Toh, D. Vail, C. London, P. Bergman, L. Barber, M. Breen, B. Kitchell, E. McNeil, J.F. Modiano, S. Niemi, K.E. Comstock, E. Ostrander, S. Westmoreland, and S. Withrow The dog as a cancer model Nature Biotechnology 24 9 2006 1065 1066
10. I.D. Kurzman, E.G. MacEwen, R.C. Rosenthal, L.E. Fox, E.T. Keller, S.C. Helfand, D.M. Vail, R.R. Dubielzig, B.R. Madewell, and C.O. Rodriguez Jr. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin Clinical Cancer Research 1 12 1995 1595 1601 (Pubitemid 26028092)
11. P.A. Meyers, C.L. Schwartz, M.D. Krailo, J.H. Healey, M.L. Bernstein, D. Betcher, W.S. Ferguson, M.C. Gebhardt, A.M. Goorin, M. Harris, E. Kleinerman, M.P. Link, H. Nadel, M. Nieder, G.P. Siegal, M.A. Weiner, R.J. Wells, R.B. Womer, and H.E. Grier Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group Journal of Clinical Oncology 26 4 2008 633 638 (Pubitemid 351264359)
12. W.J. Jusko Guidelines for collection and analysis of pharmacokinetic data W.E. Evans, J.J. Schentag, W.J. Jusko, Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring 1992 Applied Therapeutics, Inc. Vancouver, WA pp. 2-1-2-43
13. D.L. Gustafson, M.E. Long, J.A. Zirrolli, M.W. Duncan, S.N. Holden, A.S. Pierson, and S.G. Eckhardt Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay Cancer Chemotherapy and Pharmacology 52 2 2003 159 166 (Pubitemid 37041350)
14. J. Kapitulnik, O. Pelkonen, U. Gundert-Remy, S.G. Dahl, and A.R. Boobis Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models Expert Opinion on Therapeutic Targets 13 7 2009 867 887
15. D.S Riddick, C. Lee, S. Ramji, E.C. Chinje, R.L. Cowen, K.J. Williams, A.V. Patterson, I.J. Stratford, C.S. Morrow, A.J. Townsend, Y. Jounaidi, C.S. Chen, T. Su, H. Lu, P.S. Schwartz, and D.J. Waxman Cancer chemotherapy and drug metabolism Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 8 2005 1083 1096 (Pubitemid 41043749)
16. C.D. Scripture, A. Sparreboom, and W.D. Figg Modulation of cytochrome P450 activity: implications for cancer therapy The Lancet Oncology 6 10 2005 780 789 (Pubitemid 41430719)
17. J.H. Beijnen, and J.H. Schellens Drug interactions in oncology The Lancet Oncology 5 8 2004 489 496 (Pubitemid 39069399)
18. D.J. Marchand, and K.W. Renton Depression of cytochrome P-450-dependent drug biotransformation by adriamycin Toxicology and Applied Pharmacology 58 1 1981 83 88 (Pubitemid 11102610)
19. J.G. Slatter, P. Su, J.P. Sams, L.J. Schaaf, and L.C. Wienkers Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metabolism and Disposition: The Biological Fate of Chemicals 25 10 1997 1157 1164 (Pubitemid 27446586)
20. V. Charasson, M.C. Haaz, and J. Robert Determination of drug interactions occurring with the metabolic pathways of irinotecan Drug Metabolism and Disposition: The Biological Fate of Chemicals 30 6 2002 731 733 (Pubitemid 34579109)
21. P. Blower, R. de Wit, S. Goodin, and M. Aapro Drug-drug interactions in oncology: why are they important and can they be minimized? Critical Reviews in Oncology/Hematology 55 2 2005 117 142 (Pubitemid 40981915)
22. I. Meijerman, J.H. Beijnen, and J.H. Schellens Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer Cancer Treatment Reviews 34 6 2008 505 520
23. E.A. Neuwelt, M.A. Pagel, B.P. Hasler, T.G. Deloughery, and L.L. Muldoon Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model Cancer Research 61 21 2001 7868 7874 (Pubitemid 33049377)
24. S Kummar, M. Gutierrez, J.H. Doroshow, and A.J. Murgo Drug development in oncology: classical cytotoxics and molecularly targeted agents British Journal of Clinical Pharmacology 62 1 2006 15 26 (Pubitemid 44195239)
25. P. Workman, E.O. Aboagye, Y.L. Chung, J.R. Griffiths, R. Hart, M.O. Leach, R.J. Maxwell, P.M. McSheehy, P.M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies Journal of the National Cancer Institute 98 9 2006 580 598 (Pubitemid 43904842)
26. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discovery Today 10 2 2005 139 147 (Pubitemid 40247812)
27. A.J. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B. van Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family The Biochemical Journal 370 Pt 3 2003 737 749 (Pubitemid 36399066)
28. O. Witt, H.E. Deubzer, T. Milde, and I. Oehme HDAC family: what are the cancer relevant targets? Cancer Letters 277 1 2009 8 21
29. H.M. Prince, M.J. Bishton, and S.J. Harrison Clinical studies of histone deacetylase inhibitors Clinical Cancer Research 15 12 2009 3958 3969
30. E.J. Calabrese, and L.A. Baldwin Chemotherapeutics and hormesis Critical Reviews in Toxicology 33 3-4 2003 305 353 (Pubitemid 36628412)
31. J. Gabrielsson, H. Dolgos, P.G. Gillberg, U. Bredberg, B. Benthem, and G. Duker Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations Drug Discovery Today 14 7-8 2009 358 372
32. G. Levy Impact of pharmacodynamic variability on drug delivery Advanced Drug Delivery Reviews 33 3 1998 201 206 (Pubitemid 28403622)